...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Fibrogenesis & Tissue Repair >HDAC inhibitors in experimental liver and kidney fibrosis
【24h】

HDAC inhibitors in experimental liver and kidney fibrosis

机译：HDAC抑制剂在实验性肝肾纤维化中的作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Histone deacetylase (HDAC) inhibitors have been extensively studied in experimental models of cancer, where their inhibition of deacetylation has been proven to regulate cell survival, proliferation, differentiation and apoptosis. This in turn has led to the use of a variety of HDAC inhibitors in clinical trials. In recent years the applicability of HDAC inhibitors in other areas of disease has been explored, including the treatment of fibrotic disorders. Impaired wound healing involves the continuous deposition and cross-linking of extracellular matrix governed by myofibroblasts leading to diseases such as liver and kidney fibrosis; both diseases have high unmet medical needs which are a burden on health budgets worldwide. We provide an overview of the potential use of HDAC inhibitors against liver and kidney fibrosis using the current understanding of these inhibitors in experimental animal models and in vitro models of fibrosis.
机译：组蛋白脱乙酰基酶（HDAC）抑制剂已在癌症的实验模型中进行了广泛研究，其中已证明抑制脱乙酰基能调节细胞存活，增殖，分化和凋亡。反过来，这导致在临床试验中使用各种HDAC抑制剂。近年来，已经探索了HDAC抑制剂在其他疾病领域中的适用性，包括纤维变性疾病的治疗。伤口愈合不良涉及由成肌纤维细胞控制的细胞外基质的连续沉积和交联，导致诸如肝和肾纤维化的疾病。两种疾病都有很高的未满足的医疗需求，这是全世界卫生预算的负担。我们提供对HDAC抑制剂在肝和肾纤维化中的潜在用途的概述，并根据目前在实验动物模型和纤维化体外模型中对这些抑制剂的了解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号